Shares of CytomX Therapeutics Inc. (NASDAQ:CTMX) were up 8.3% during mid-day trading on Friday . The company traded as high as $11.50 and last traded at $11.46, with a volume of 58,086 shares traded. The stock had previously closed at $10.58.

Several analysts have weighed in on the stock. Zacks Investment Research lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, April 28th. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of CytomX Therapeutics in a report on Tuesday, May 10th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $19.00.

The company’s market capitalization is $410.31 million. The firm has a 50 day moving average of $10.22 and a 200-day moving average of $12.00.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.02. On average, analysts forecast that CytomX Therapeutics Inc. will post ($1.59) EPS for the current fiscal year.

In related news, Director Timothy M. Shannon sold 48,427 shares of the company’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $10.07, for a total value of $487,659.89. Following the completion of the transaction, the director now directly owns 134 shares in the company, valued at $1,349.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ix L.P. Canaan sold 111,498 shares of the company’s stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $10.01, for a total value of $1,116,094.98. The disclosure for this sale can be found here.

CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.